Wong et al. describe in Biochemical Society Transactions how open collaboration and an open drug discovery model, like the one used by M4K Pharma, can help overcome the challenges faced while researching therapies for rare paediatric brain tumours such as DIPG.
Fostering Open Collaboration for Paediatric Cancer Drug Development
Previous
Previous
Oxford Team Supports Brain Tumour Charity’s Twilight Walk
Next
Next